Food composition and pharmaceutical composition for inhibiting sjogren's syndrome each containing bifidobacterium pseudocatenulatum c-rapo (kctc13986bp) and bifidobacterium bifidum att (kctc13474bp)
AssigneeBifido Co., Ltd.
InventorsGeun Eog JI, Myeong Soo PARK
Life of this patent
Estimating the term…
Abstract
Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.
Claims5
-4. (canceled)
A method of inhibiting Sjogren's syndrome in a subject in need thereof comprising administrating to the subject a food composition comprising a strain of Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP).
A method of preventing or treating Sjogren's syndrome in a subject in need thereof comprising administrating to the subject a pharmaceutical composition comprising a strain of Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP).
A method of inhibiting Sjogren's syndrome in a subject in need thereof comprising administrating to the subject a food composition comprising a strain of Bifidobacterium bifidum ATT (KCTC13474BP).
A method of preventing or treating Sjogren's syndrome in a subject in need thereof comprising administrating to the subject a pharmaceutical composition comprising a strain of Bifidobacterium bifidum ATT (KCTC13474BP).
Dependencies are inferred from the claim text.